高级顾问
Rich Racine律师在知识产权领域有超过30多年的丰富经验,他为客户制定成功的法律策略来帮助他们高效经济地实现商业目标。作为事务所多年的管理合伙人和事务所管理委员会主席,他深刻理解认识到法律和商业之间的相互作用和影响,并将其运用至法律实务之中。
Richard Racine律师的执业范围几乎涉及知识产权法律的所有方面,尤其侧重于地方法院专利诉讼、尽职调查、出具法律意见以及专利组合发展与管理。他与不同技术领域的客户密切合作,共同制定和执行策略,以帮助这些公司最大限度地获取、保护以及执行知识产权。
Racine律师具备丰富的诉讼经验,在联邦地方法院的很多案件中都负责过重要职责,包括从最初的诉状阶段到调查取证、动议、专利权利要求解释及审判。他的大部分诉讼业务涉及复杂的重大专利侵权纠纷。Racine律师被Legal 500 U.S. 评为国际贸易委员会(ITC)专利诉讼业务优秀律师。他在为"重磅炸弹"级药品的简明新药申请(ANDA)诉讼中担任重要角色。此外,他还非常熟悉《药品价格竞争与专利期补偿法》、专利法以及食品药品管理局法规之间的相互影响。
Racine律师为许多有关技术领域(尤以制药和化学领域为主)提供广泛而精良的专业法律意见和进行尽职调查。他就复杂的专利有效性、可执行性以及专利侵权问题提供了无数的专业法律意见。这些意见中有许多为诉前意见,或被作为合并、收购、尽职调查、专利组合评估发展或授权机会的一部分。
Racine律师经常发表有关专利保护与诉讼的演讲,特别是法律意见与尽职调查业务和美国发明法案(AIA)等话题。他主持过多个会议和项目,包括专利资源团体(Practice Resources Group)、《知识产权管理》(Managing Intellectual Property)、知识产权所有者协会 (Intellectual Property Owners Association)、生物技术产业组织 (the Biotechnology Industry Organization,BIO)、希尔德布兰特学会 (the Hildebrandt Institute)、食品药品法学院(the Food and Drug Law Institute)、中国500强企业论坛、以及西南法律基金会 (Southwestern Legal Foundation)。他也每年在中国举办课程和讲座。
Racine律师担任过许多本所的管理和领导职务。他曾担任事务所管理合伙人和事务所主席。他也是事务所管理和薪酬委员会成员;并有两段时期担任过事务所化学业务组组长。
Certain Sulfentrazone, Sulfentrazone Compositions, and Processes for Making Sulfentrazone
Defended two Chinese agro-chemical companies, defeating a petition for a temporary exclusion order and prevailing at trial, holding the patent invalid and not infringed.
337-TA-914, ITC, Judge Lord
Cephalon, Inc. v. Sun Pharmaceuticals Industries, Inc.
3:11-cv-05474, D.N.J., Judges Arpert, Shipp, Wolfson
Merck Sharp & Dohme Corp. v. GlaxoSmithKline Biologicals SA
IPR2018-01229, -01234, -01236, -01237; IPR2019-00230, -00241, PTAB, Judges Snedden, Kokoski, Smith
Pfenex Inc. v. GlaxoSmithKline Biologicals SA
IPR2019-01027, -01028, PTAB
1:90-cv-07515, N.D. Ill., Judge Rovner
W.R. Grace & Co. v. Viskase Corp.
1:90-cv-05383, N.D. Ill., Judge Conlon
Conference
Paragraph IV Disputes Master Symposium Paragraph IV Disputes Master Symposium
September 19-20, 2016
Chicago
Lecture
The Fourth Annual China IP Forum The Fourth Annual China IP Forum
January 10-11, 2014
Beijing
Panel Discussion
Intellectual Property Throughout the Drug Development Lifecycle: Opportunities and Challenges Intellectual Property Throughout the Drug Development Lifecycle: Opportunities and Challenges
July 17, 2012
Washington
Conference
Outsourcing Drug Discovery: Partnership and Licensing Tactics Outsourcing Drug Discovery: Partnership and Licensing Tactics
May 9-10, 2012
Philadelphia
Articles
Challenges Facing Chinese Companies Exporting to the United States Challenges Facing Chinese Companies Exporting to the United States
January 5, 2012
Imp-Exp Executive MagazinePress Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyPress Release
29 Finnegan Attorneys Ranked by Best Lawyers 29 Finnegan Attorneys Ranked by Best Lawyers
August 18, 2022
U.S. News—Best LawyersPress Release
Twenty Finnegan Attorneys Recognized by Best Lawyers Twenty Finnegan Attorneys Recognized by Best Lawyers
August 20, 2021
U.S. News—Best LawyersAnnouncement
Best Lawyers Recognizes 21 Finnegan Attorneys Best Lawyers Recognizes 21 Finnegan Attorneys
August 28, 2020
Press Release
31 Finnegan Attorneys Named Managing Intellectual Property IP Stars 31 Finnegan Attorneys Named Managing Intellectual Property IP Stars
May 4, 2020
Managing Intellectual PropertyPress Release
Managing Intellectual Property Recognizes 32 Finnegan Attorneys Worldwide as “IP Stars” Managing Intellectual Property Recognizes 32 Finnegan Attorneys Worldwide as “IP Stars”
May 20, 2019
Managing Intellectual PropertyDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.